Paper Details

  1. Home
  2. Paper Details

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.

Author: , CreutzbergE C, FokkensB, HensingC A J, HopW C J, KuipersA F, PasmaH R, PostmaD S, PrinsJ, WoutersE F M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Inhaled corticosteroids (ICS) are recommended for people with COPD who have poor lung function and frequent flare-ups, but they only slightly slow the decline in lung function. Combining ICS with a long-acting beta2 agonist (LABA) might help stabilize COPD, but it's unclear what happens if you stop taking ICS.
Paper Details　
Original Abstract of the Article :
Guidelines recommend inhaled corticosteroids (ICS) as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted and frequent exacerbations, although they have only a small preventive effe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1747438/

データ提供：米国国立医学図書館（NLM）

Fluticasone Propionate Withdrawal in COPD: A Cause for Concern

The world of [respiratory medicine] is a challenging terrain, and managing [chronic obstructive pulmonary disease (COPD)] requires a delicate balance of treatments. This study, like a careful traveler navigating a sandstorm, explores the impact of withdrawing [fluticasone propionate] from combined treatment with [salmeterol] in patients with COPD.

Withdrawal of Fluticasone Propionate: A Detrimental Impact

The researchers discovered that withdrawing fluticasone propionate from combined treatment led to an immediate and sustained deterioration in COPD symptoms. This finding is like a sudden sandstorm in a desert, disrupting stability and causing significant distress. It highlights the importance of careful consideration before discontinuing inhaled corticosteroids in patients with COPD.

Navigating Treatment Decisions with Caution

This study provides a crucial reminder that treatment decisions must be made with careful consideration and close monitoring. Discontinuing medications, especially those with potential long-term benefits, should not be taken lightly. It's essential to work closely with a healthcare provider to develop a personalized treatment plan that balances the risks and benefits of various therapies.

Dr.Camel's Conclusion

This study underscores the importance of carefully considering the potential consequences of medication withdrawal in patients with COPD. By understanding the complex interplay between medications and disease progression, we can better manage COPD and improve the quality of life for those living with this condition. It's a reminder that the journey through the desert of respiratory medicine requires careful observation, informed decision-making, and a commitment to long-term management.

Date :
  1. Date Completed 2005-06-27
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

15923248

DOI: Digital Object Identifier

PMC1747438

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.